Literature DB >> 26682688

The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils.

Asa Hatami1, Sanaz Monjazeb1, Charles Glabe1,2.   

Abstract

Recently we reported that several monoclonal antibodies that recognize linear segments of amyloid-β (Aβ) also recognize amyloid fibrils, but not monomers of unrelated sequences, indicating that recognition of a linear sequence segment is not a reliable indicator of sequence specificity. We asked whether any of the commonly used commercially available Aβ antibodies also recognize fibrils of unrelated sequence. Here we report that 4G8, which recognizes residues 18-23 of the Aβ sequence and is widely believed to be sequence-specific, also recognizes fibrils formed from α-synuclein and islet amyloid polypeptide (IAPP). The recognition of amyloid fibrils is aggregation-dependent because 4G8 does not recognize α-synuclein or IAPP monomer. 4G8 also stains fibrillar α-synuclein aggregates in human multiple system atrophy brain where it colocalizes with anti-α-synuclein monoclonal antibody LB509 immunoreactivity. We also found that LB509 recognizes Aβ fibrils, but not monomer, indicating that generic epitope-reactive antibodies are also produced in response to α-synuclein immunization. Taken together, our results indicate that generic fibril conformational epitope specificity may be a pervasive property among monoclonal antibodies raised against amyloid-forming antigens and that the specificity of their immunoreactivity should be rigorously established and otherwise interpreted with caution.

Entities:  

Keywords:  Amyloid; IAPP; amyloid-beta; conformation; monoclonal antibody; synuclein

Mesh:

Substances:

Year:  2016        PMID: 26682688     DOI: 10.3233/JAD-150696

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  8 in total

1.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

2.  The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain.

Authors:  Jaap Goudsmit
Journal:  Eur J Epidemiol       Date:  2016-03-26       Impact factor: 8.082

3.  Erratum to: Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?

Authors:  Sally Hunter; Carol Brayne
Journal:  J Negat Results Biomed       Date:  2017-03-08

Review 4.  Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?

Authors:  Sally Hunter; Carol Brayne
Journal:  J Negat Results Biomed       Date:  2017-01-26

5.  Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8.

Authors:  Ibtisam Baghallab; Jorge Mauricio Reyes-Ruiz; Khalid Abulnaja; Etimad Huwait; Charles Glabe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Inhibition of AMD-Like Pathology With a Neurotrophic Compound in Aged Rats and 3xTg-AD Mice.

Authors:  Yinghua Liu; Wei Wei; Narjes Baazaoui; Fei Liu; Khalid Iqbal
Journal:  Front Aging Neurosci       Date:  2019-11-19       Impact factor: 5.750

7.  Translocation of Distinct Alpha Synuclein Species from the Nucleus to Neuronal Processes during Neuronal Differentiation.

Authors:  Katharina Pieger; Verena Schmitt; Carina Gauer; Nadja Gießl; Iryna Prots; Beate Winner; Jürgen Winkler; Johann Helmut Brandstätter; Wei Xiang
Journal:  Biomolecules       Date:  2022-08-12

Review 8.  The Erythrocytic Hypothesis of Brain Energy Crisis in Sporadic Alzheimer Disease: Possible Consequences and Supporting Evidence.

Authors:  Elena Kosenko; Lyudmila Tikhonova; Gubidat Alilova; Amparo Urios; Carmina Montoliu
Journal:  J Clin Med       Date:  2020-01-12       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.